DNA Script Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 150
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $197M
Latest Deal Amount
  • Investors
  • 25

DNA Script General Information

Description

Developer of an enzymatic DNA synthesis platform designed to facilitate genome-scale synthesis. The company's platform features a novel biochemical process for nucleic acid synthesis based on the use of highly efficient enzymes to provide rapid, high-quality production of important genomic experimental precursors, such as an oligonucleotide, enabling molecular biology researchers to accelerate their experiments and development of new therapeutics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 67 avenue de Fontainebleau
  • 94270 Le Kremlin-Bicêtre
  • France
+33 01 00 00 00 00

DNA Script Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

DNA Script Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series C) 26-Oct-2021 $197M 00000 00000 Completed Generating Revenue
7. Later Stage VC (Series B) 29-Jul-2020 000.00 00000 00000 Completed Generating Revenue
6. Grant 10-Jul-2018 00.00 000.00 Completed Generating Revenue
5. Grant 04-Apr-2018 00.00 000.00 Completed Generating Revenue
4. Grant 01-Feb-2018 00.000 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 12-Sep-2017 000.00 000.00 000.00 Completed Generating Revenue
2. Seed Round 30-May-2016 $2.82M $2.82M 00.000 Completed Generating Revenue
1. Accelerator/Incubator 01-Jul-2015 Completed Generating Revenue
To view DNA Script’s complete valuation and funding history, request access »

DNA Script Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ADP 2021 000,000 00.000000 0000.0 0000.0 00 0000.0 00.000
ADP 2019 00,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 000 00.000000 000.00 000.00 000.00 0.000
ADP 2019 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
ADP 2017 000,000 00.000000 000.00 000.00 00 000.00 00.000
ADP 2016 58,140 $0.116067 $49.91 $49.91 1x $49.91 7.47%
Ordinary 55,989 $0.116067
To view DNA Script’s complete cap table history, request access »

DNA Script Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an enzymatic DNA synthesis platform designed to facilitate genome-scale synthesis. The company's platform f
Biotechnology
Le Kremlin-Bicêtre, France
150 As of 2022
00000
0000 0000-00-00
00000000000 00000

00000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt
00000 0000000000 0000000000 0000000
Cambridge, United Kingdom
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00

0000000

lore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui off
0000000000000
London, United Kingdom
0 As of 0000
00.000
000000&0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DNA Script Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evonetix Venture Capital-Backed Cambridge, United Kingdom 00 000.00 00000000000 000.00
0000000 00000000 Formerly VC-backed London, United Kingdom 0 00.000 000000&0 00.000
0000000 Venture Capital-Backed Cambridge, United Kingdom 00 000.00 00000000000 000.00
0000 00000000 Venture Capital-Backed Toronto, Canada 000 00000 00000000000 00000
000000 00000000 Formerly VC-backed Saint Sulpice, Switzerland 000 00000 000000000 00000
You’re viewing 5 of 29 competitors. Get the full list »

DNA Script Patents

DNA Script Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210300961-A1 Method for preparing 3'-o-amino-2'-deoxyribonucleoside-5'-triphosphates Pending 30-Mar-2020 00000000
EP-3744854-A1 Variants of terminal deoxynucleotidyl transferase and uses thereof Withdrawn 28-May-2019 0000000000 0
CA-3129393-A1 Efficient product cleavage in template-free enzymatic synthesis of polynucleotides. Pending 12-Feb-2019 000000000
AU-2020223456-A1 Efficient product cleavage in template-free enzymatic synthesis of polynucleotides. Pending 12-Feb-2019 000000000
US-20210254114-A1 Efficient product cleavage in template-free enzymatic synthesis of polynucleotides Pending 12-Feb-2019 C12P19/34
To view DNA Script’s complete patent history, request access »

DNA Script Executive Team (7)

Name Title Board Seat Contact Info
Thomas Ybert Ph.D Co-Founder, Chief Executive Officer & Board Member
Philippe Lyko Chief Financial Officer
Sylvain Gariel Co-Founder, Chief Operating Officer & Board Member
Xavier Godron Co-Founder & Chief Technology Officer
Chris Barbazette Chief Commercial Officer
You’re viewing 5 of 7 executive team members. Get the full list »

DNA Script Board Members (16)

Name Representing Role Since
Bonnie Anderson Self Board Member 000 0000
Catherine Moukheibir Self Chair of Audit Committee 000 0000
Don Kania Ph.D Self Chairman 000 0000
Eli Casdin Self Board Member 000 0000
Heiner Dreismann Ph.D Kurma Partners Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

DNA Script Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DNA Script Investors (25)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
ArrowMark Partners Asset Manager Minority 000 0000 000000 0
Baillie Gifford Asset Manager Minority 000 0000 000000 0
Catalio Capital Management Venture Capital Minority 000 0000 000000 0
Coatue Management PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 25 investors. Get the full list »